Get started
Author

Anique L.C. Verpoorte

Observed institution: Leiden University Medical Center
ORCID: 0009-0008-7722-1609
Observed ORCID: 0009-0008-7722-1609
OpenAlex ID: A5117449271
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al. · Clinical Cancer Research · 6
Data from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Figure S6 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S4 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S2 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S5 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Table S2 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Figure S3 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Figure S1 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
PDF
Supplementary Table S1 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S4 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S5 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Supplementary Table S3 from Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα
2025 · Els M.E. Verdegaal, Anique L.C. Verpoorte, et al.
Works count: 13
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type